BHI Elects MedImmune's Reg Seeto, M.D. to Board of Directors
ROCKVILLE, Md. and BALTIMORE, Dec. 19, 2013 /PRNewswire/ -- BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today that Reg Seeto, M.D., has been appointed to the BHI Board of Directors. Dr. Seeto currently serves as Vice President, Head of Partnering & Strategy at MedImmune, the global biologics research and development arm of AstraZeneca.
"It is a pleasure to welcome Reg to the BHI Board of Directors," said Doug Liu, Chair, BHI Board of Directors, and Senior Vice President of Global Operations for Qiagen. "Reg's background in business development and partnering strategy will be an important asset to our Board as we give counsel to BHI in its fostering of startups in Central Maryland. We look forward to his contributions to this Board, to the BHI organization, and to the biohealth startup community."
Dr. Seeto rejoined the MedImmune Leadership Team in 2013 to lead the Partnering and Strategy Group after having spent a year as an executive abroad for AstraZeneca. He is responsible for MedImmune's Business Development and Strategy teams, which deliver external partnership strategy for the organization.
"It is an honor to be appointed to the BHI Board of Directors," said Dr. Seeto. "MedImmune has a strong interest in strengthening Maryland as a premiere bioscience cluster, and I look forward to working with BHI to advance its mission of developing Central Maryland into a center for commercialization and entrepreneurialism."
From 2011 to 2012, Dr. Seeto was on an expatriate assignment as the President of AstraZeneca Thailand, where he was the first MedImmune executive to participate in a talent exchange and development program with AstraZeneca. Under his leadership, the organization achieved its sales targets for the first time in five years and was awarded a company leadership award for management of the country's worst floods in more than half a century.
Dr. Seeto originally joined MedImmune in 2008 as the Vice President of Global Strategic Marketing and Portfolio Management where he worked closely with the R&D leadership team. He was later promoted to the MedImmune Executive Team (MET) and established the Corporate Development and Strategy Group. Dr. Seeto has previous experience with Schering Plough/Organon Biosciences and Boehringer Ingelheim Pharmaceuticals. His earlier work experience included serving as a consultant at McKinsey & Company and he started his career as a medical doctor involved in both clinical practice and research. He has also served as first author for papers published in peer-reviewed journals. Dr. Seeto holds his medical degree (with honors) from the University of Sydney, Australia
About BioHealth Innovation, Inc.
BioHealth Innovation, Inc., is a regional innovation intermediary focused on commercializing market-relevant bio-health innovations and increasing access to early-stage funding in Maryland. Learn more at www.biohealthinnovation.org.
SOURCE BioHealth Innovation, Inc.